Here’s what we know about the VA’s new GLP-1 study

Key Points:

• The Department of Veterans Affairs (VA) is launching the largest study to date on the use of GLP-1 semaglutide medications to treat alcohol use disorder, aiming to provide definitive evidence for its effectiveness and potentially influence U.S. regulatory approval.
• Semaglutide, originally a diabetes and weight-loss drug, mimics the GLP-1 hormone and may offer a more accessible and palatable treatment option for alcohol addiction, particularly in primary care settings.
• The trial will involve over 600 veterans with moderate to severe alcohol use disorder, who will self-administer weekly doses of semaglutide or placebo, with researchers monitoring cravings, addiction symptoms, and overall health impacts.
• Unlike traditional treatments requiring intensive therapy, this study allows veterans to receive brief medical management sessions without mandatory mental health treatment, aiming to simplify and broaden access to care.
• Previous smaller studies have shown semaglutide significantly reduces heavy drinking days and alcohol consumption, and the VA hopes this larger trial will support FDA approval for semaglutide as an official treatment for alcohol addiction.